A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

RhoVac AB, a Swedish cancer immunotherapy company, announces today, April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac’s clinical phase IIb study, “BRaVac”, in prostate cancer.

Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States, and it is widely recognised and one of the leading hospitals in the US, and indeed in the world, and as such RhoVac is extremely proud to declare its participation in the BRaVac trial.

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track Designation. Immediately after the news on the Fast Track Designation was made public, Mount Sinai contacted RhoVac via its Scientific Advisory Board member, Professor Per-Anders Abrahamsson, who brokered the connection to RhoVac management. It is an honour for RhoVac, and a recognition of the potential of its drug candidate, that such a world leading hospital spontaneously seeks to join its clinical trial.

The site initiation visit is held, today, April 21st , and the study will be supervised at Mount Sinai by Professor Ash Tewari. In the trial, RhoVac’s drug candidate, RV001, will be used in prostate cancer patients that have previously had a prostatectomy or definitive radiation therapy, but that now have suffered a “Biochemical Recurrence” (rising PSA) but who still have not developed detectable metastases. The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for development.

RhoVac CEO, Anders Månsson, comments: “I was of course delighted when I learned that Mount Sinai wanted to join our study. I regard this as yet another example of the recognition that the Fast Track Designation has brought us already, and I am happy that we could get started so quickly. I wish Mount Sinai welcome on board the trial team, and I look forward to our collaboration”.

SourceRhoVac
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy